FSNUY
OQX Fresenius SE & Co. KGaA Sponsored ADR$12.40 ↓ -0.26 (-2.08%) Trading Down from the previous close of $12.66, $0.21 below the day’s high of $12.61
- YTD change
- -13.47%
- vs 20-day SMA
- -5.13%
- vs 200-day SMA
- -4.90%
Price ranges
Price & Performance
-0.06 (-0.48%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 63.5% away from all-time highs of $33.93
- FSNUY is down 13% since the beginning of the year
- FSNUY is down 12% over the past 12 months
- FSNUY is down 4% over the past 1 month
FSNUY reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -9.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.05
- Last 5 days
- -6.20%
- vs 8-day SMA
- -5.21%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
Competitor comparison
| Ticker | Company | Price | Change |
|---|---|---|---|
| SRTOY | Sartorius Stedim Biotech SA Unsponsored ADR | $25.49 | +2.16% |
| FSPKF | Fisher & Paykel Healthcare Corporation Limited | $26.01 | +1.60% |
| HSIC | Henry Schein, Inc. | $83.97 | -1.18% |
| EBOSY | EBOS Group Limited Sponsored ADR | $23.30 | +3.15% |
| EKTAY | Elekta AB Unsponsored ADR Class B | $5.23 | -0.48% |
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.